STORYLINE: A manufacturer must ensure that implantable device be accompanied with an IFU (labeling) that contains the overall constituent composition material information commensurate with EU MDR 2017/745 Annex 1, (GSPR) Chapter III, 23.4 (u) qualitative and quantitative material composition information to which patients may be exposed and if applicable EU MDR 2017/745 Annex 1, (GSPR) Chapter III, 23.2 (f) substances of concern [CMD 1A/1B ED] information.
PRIMARY PERSONA AND SUPPORTING PERSONAS WHERE RELEVANT: Manufacturer – Engineering, Biological Safety, Regulatory Affairs, Clinical Affairs, Labeling, Design Quality, Supply Chain.
INFORMATION NEEDS: The manufacturer needs to collect, validate, and disseminate detailed constituent implant material information that is present in concentrations of .1% wt. by wt. or greater. The information is then consumed within European market implant IFUs to meet the EU MDR 2017/745 Annex 1, (GSPR) Chapter III, 23.4 (u) and if applicable EU MDR 2017/745 Annex 1, (GSPR) Chapter III, 23.2 (f) substances of concern [CMD 1A/1B ED] information requirements.
ROUTE(S) OF ACCESS TO INFORMATION: Today: The public material information is typically published within an international material standard, (e.g. ISO, ASTM, etc.) and related clause level chemical composition table. The constituent materials information must also be assessed by the manufacturer to published CLP [CMR 1A/1B ED] information available on the European Chemicals Agency Database (https://echa.europa.eu), which is time consuming and is only as accurate as in the point of time the information is accessed on ECHA (e.g. CLP regulation information evolves over time).
TRUSTWORTHINESS/QUALITY CONSIDERATIONS: The provided implant related qualitative and quantitative information is typically reliable as it has been gathered, validated and reviewed under the respective manufactures quality system management change and release control procedures.
PRELIMINARY KPI CONSIDERATIONS: